Video Journal of Oncology (VJOncology)

NEW #podcast episode: 'Updates in #immunotherapy for #skincancer’ 🎧 In this episode we cover: 🔦 Impact of T-Cell therapies, such as #lifileucel, in patients with #melanoma 🔦 Results of the 7-year CheckMate 238 trial (NCT02388906) of #nivolumab 🔦 Effective #sequencing of treatments in the #SECOMBITtrial (NCT02631447) 🔦 Challenges in managing immunotherapy related #adverseevents With leading experts:  🌟 Omid Hamid, MD, The Angeles Clinic & Research Institute, Inc. 🌟 Paolo A. Ascierto, MD, IRCCS Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy 🌟 Georgina Long, PhD, MBBS, FRACP, FAHMS, Medicine and Health - University of Sydney 🌟 Karijn Suijkerbuijk, MD, PhD, UMC Utrecht Give it a listen 👉https://lnkd.in/eqnYMHRa Use the time codes to skip to your favourite part of each episode 👀 SUBSCRIBE so you don't miss any future episodes📱 #VJOncology

🎥 Missed #ESMOGI24? No worries! Catch up on all the latest #GIcancer research and expert interviews 👉 https://lnkd.in/drfT7Wqv Stay informed with our exclusive coverage! 🕺 #VJOncology #Oncologynews #GISM #CRCSM #PancSM #ESOCsm #STCsm #HPBCsm

NEW from #ASCO2024 | Gut microbiome and treatment outcomes in #HR+/#HER2- #breastcancer🎥 🇺🇸 Alexis Ann LeVee, MD, City of Hope, comments on the utility of #stool #microbialprofiling in a Phase I/II study (NCT02778685), which assessed #palbociclib, #pembrolizumab, and #endocrinetherapy (ET) in patients with HR+/HER2- #metastaticbreastcancer (#MBC) #Gutmicrobiome profiling suggests specific bacterial taxa and #metabolic pathways are associated with treatment response, indicating a potential #biomarker for #immune #checkpointinhibitor efficacy Learn more 👉 https://lnkd.in/emPDBttN #VJOncology #Oncologynews #BCsm

This is an important pathway in cancer signaling, including #melanoma. Targeting CXCR1/2 signaling is not new, but this *new* small molecule inhibitor managed to generate responses in PD-1 refractory disease, including those whose #melanoma had previously reponsded to immune checkpoint blockade.

NEW from #ASCO2024 | KEYNOTE-361: #ctDNA as a #biomarker in advanced #urothelialcarcinoma 🎥 🇺🇸 Tom Powles, MBBS, MRCP, MD, Barts Cancer Institute (Queen Mary University of London), provides an overview of a retrospective analysis from the Phase III KEYNOTE-361 trial (NCT02853305), investigating the prognostic value of #circulatingtumorDNA (#ctDNA) in advanced #urothelialcarcinoma (UC) treated with #pembrolizumab #monotherapy versus #chemotherapy 🌟Lower baseline #ctDNA levels correlated with improved outcomes in patients receiving #pembrolizumab 🌟Distinct #ctDNA response patterns were observed, with stronger associations between #ctDNA reductions and #clinical outcomes seen in the #pembrolizumab arm Learn more 👉 https://lnkd.in/erg8G5FE #VJOncology #Oncologynews

NEW from #ASCO2024 | BEAT-SC: Phase III trial of #bevacizumab or #placebo with #atezolizumab & #chemo in extensive-stage #SCLC 🎥 🇺🇸 Melina Elpi Marmarelis, MD, University of Pennsylvania, discusses the efficacy and safety of combining #bevacizumab with #atezolizumab and platinum-based #chemotherapy in extensive-stage #smallcelllungcancer (ES-#SCLC) patients from Japan and China 🌟The BEAT-SC trial showed that adding #bevacizumab to the regimen significantly increased progression-free survival (PFS) compared to #placebo 🌟However, the first interim analysis for overall survival (OS) did not show a significant improvement. The combination was well-tolerated, with similar treatment-related adverse events between groups. Further OS follow-up is ongoing. Learn more 👉 https://lnkd.in/eHZfhQUV #VJOncology #Oncologynews #LCsm

Dr. Meredith McKean presented results from pivotal melanoma trials at #ASCO24, including KEYMAKER-U02A, IMC-F106, and SC-682. Discover the latest advancements in melanoma treatment in this Video Journal of Oncology (VJOncology) video: https://lnkd.in/gXfdrdmj #ASCO24 #Melanoma #CancerResearch #Oncology #Immunotherapy #ClinicalTrials

Join Dr. Meredith McKean in exploring the potential of JZP898, an IFN-α, and Pembrolizumab in treating advanced solid tumors. Watch her detailed evaluation on Video Journal of Oncology (VJOncology): https://lnkd.in/gzjRxJY7 #ASCO24 #CancerResearch #Oncology #Immunotherapy #SolidTumors #MedicalResearch

NEW from #ASCO2024 | Evaluating JZP898, an IFN-α and #pembrolizumab in advanced #solidtumors 🎥 🇺🇸 Meredith McKean, MD, MPH, Sarah Cannon Research Institute, shares findings from a Phase I, first-in-human study (NCT06108050) of JZP898, a conditionally activated prodrug of interferon alpha (IFN-α), alone or combined with #pembrolizumab in patients with advanced or #metastatic #solidtumors 🌟 The study aims to determine the maximum tolerated dose, safety, tolerability, #pharmacokinetics, and preliminary #antitumor activity 🌟 The combination is designed to enhance antitumor effects while minimizing systemic toxicity 🌟 Primary endpoints include dose-limiting toxicities and objective response rate, with secondary endpoints covering pharmacokinetics and overall survival Learn more 👉 https://lnkd.in/gzjRxJY7 #VJOncology #Oncologynews

The Annual Guard Consortium symposium approaches - Daniel Castellano Video Journal of Oncology (VJOncology) The Uromigos Toni Choueiri Petros Grivas #HealthCare #OncoDaily #Oncology #Cancer